Recent Updates
Recently added Catalysts
EBS Positive Sentiment

Emergent Biosolutions Reports Third Quarter 2026 Financial Results

Monday, November 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Emergent BioSolutions reported third-quarter financial results for 2026, achieving revenue of $110.0 million, which aligned with their guidance. The results were largely driven by their diverse portfolio in biodefense and medical countermeasures. CEO Joe Papa emphasized the company's commitment to disciplined execution during their multi-year transformation.

Market Sentiment Analysis

POSITIVE FACTORS

  • Revenue of $110.0 million met guidance.
  • Diverse biodefense and medical countermeasures portfolio.
  • Focus on disciplined execution in transformation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+70%
120-day peak, hindsight
Typical move
8%
average across 2 past catalysts
Lead asset
COVID-HIG
Phase 1 · SARS-CoV-2 Infection

Full Press Release Details

GAITHERSBURG, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2026. “Emergent's third-quarter results, which include revenue of $110.0 million inline with our guidance, were primarily driven by our diverse biodefense/medical countermeasures and naloxone portfolio, underscoring the importance of disciplined execution as we advance our multi-year transformation,” said Joe Papa, president and chief executive of

Frequently Asked Questions

What were Emergent's Q3 2026 revenues?

Emergent reported revenues of $110.0 million for Q3 2026.

What drove Emergent's Q3 2026 results?

The results were driven by their biodefense and medical countermeasures portfolio.

Who is the CEO of Emergent BioSolutions?

Joe Papa is the president and CEO of Emergent BioSolutions.

Did Emergent meet its revenue guidance?

Yes, Emergent's revenue of $110.0 million was in line with their guidance.

ShareAdd on Google
Tags: EBS Emergent BioSolutions Q3 2026 financial results biodefense
Last updated: Nov 2, 2026

Biotech snapshot

Cash runway
$140M liquidity · $0M/mo burn
Low dilution risk
Lead asset
COVID-HIGPhase 1
SARS-CoV-2 Infection →

Catalyst track record

+70%
best trade around EBS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for EBS.

See every catalyst's timing & PoA →